Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Lifitegrast Eye Drops in Healthy Subjects：Phase I Study
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT07040826
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, China
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Phase 3
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 430
- Registration Number
- NCT07025239
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Phase 2
Not yet recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Drug: QL2109 or Daratumumab
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT07018050
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus
Phase 1
Not yet recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: QLS4131 for Injection.
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT07001839
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
Phase 3
Not yet recruiting
- Conditions
- Chemotherapy-induced Peripheral Neuropathy (CIPN)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 352
- Registration Number
- NCT06994507
The Food Effect on Pharmacokinetics Study of QLC1101 in Healthy Subjects
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06980909
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06954246
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Phase 1
Not yet recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: QLC1101+QL1203Drug: QLC1101+QL2107Drug: QLC1101+QL1706Drug: QLC1101+docetaxel
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06949761
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: QLS31905 for InjectionDrug: QL2107 Injection
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06942767
To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
Phase 4
Not yet recruiting
- Conditions
- Transthyretin Amyloid Polyneuropathy
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06940336